LeMaitre Vascular (NASDAQ:LMAT) Rating Increased to Buy at StockNews.com

StockNews.com upgraded shares of LeMaitre Vascular (NASDAQ:LMATFree Report) from a hold rating to a buy rating in a research note released on Friday.

LMAT has been the topic of a number of other reports. Roth Mkm restated a buy rating and issued a $100.00 price objective on shares of LeMaitre Vascular in a report on Friday, May 31st. Roth Capital upgraded LeMaitre Vascular to a strong-buy rating in a research note on Friday, May 31st. Barrington Research raised their price objective on LeMaitre Vascular from $69.00 to $79.00 and gave the company an outperform rating in a research note on Friday, May 3rd. JMP Securities lifted their target price on LeMaitre Vascular from $72.00 to $77.00 and gave the stock a market outperform rating in a research report on Friday, May 3rd. Finally, Stifel Nicolaus raised LeMaitre Vascular from a hold rating to a buy rating and raised their price target for the stock from $59.00 to $75.00 in a report on Friday, April 26th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and a consensus target price of $77.57.

Check Out Our Latest Stock Analysis on LMAT

LeMaitre Vascular Trading Up 1.6 %

Shares of NASDAQ LMAT opened at $81.38 on Friday. LeMaitre Vascular has a twelve month low of $44.27 and a twelve month high of $81.68. The stock has a 50 day moving average of $73.34 and a two-hundred day moving average of $64.98. The stock has a market cap of $1.83 billion, a P/E ratio of 53.89, a P/E/G ratio of 2.44 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMATGet Free Report) last posted its earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.05. The company had revenue of $53.48 million for the quarter, compared to analyst estimates of $51.50 million. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. LeMaitre Vascular’s revenue was up 13.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.27 earnings per share. As a group, research analysts predict that LeMaitre Vascular will post 1.77 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, May 30th. Stockholders of record on Thursday, May 16th were issued a $0.16 dividend. The ex-dividend date was Wednesday, May 15th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.79%. LeMaitre Vascular’s payout ratio is presently 42.38%.

Insider Activity at LeMaitre Vascular

In other news, CEO George W. Lemaitre sold 8,000 shares of LeMaitre Vascular stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $75.30, for a total value of $602,400.00. Following the completion of the sale, the chief executive officer now directly owns 2,079,128 shares of the company’s stock, valued at approximately $156,558,338.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other LeMaitre Vascular news, Director David B. Roberts sold 5,025 shares of LeMaitre Vascular stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $75.62, for a total transaction of $379,990.50. Following the transaction, the director now directly owns 14,114 shares in the company, valued at $1,067,300.68. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO George W. Lemaitre sold 8,000 shares of LeMaitre Vascular stock in a transaction dated Wednesday, May 8th. The stock was sold at an average price of $75.30, for a total value of $602,400.00. Following the transaction, the chief executive officer now owns 2,079,128 shares in the company, valued at $156,558,338.40. The disclosure for this sale can be found here. Insiders sold 87,431 shares of company stock valued at $6,627,520 in the last three months. Corporate insiders own 10.79% of the company’s stock.

Institutional Trading of LeMaitre Vascular

Several hedge funds and other institutional investors have recently modified their holdings of the company. Conestoga Capital Advisors LLC raised its stake in shares of LeMaitre Vascular by 0.3% in the 1st quarter. Conestoga Capital Advisors LLC now owns 1,932,917 shares of the medical instruments supplier’s stock valued at $128,268,000 after purchasing an additional 4,946 shares during the period. Vanguard Group Inc. raised its stake in shares of LeMaitre Vascular by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 1,553,834 shares of the medical instruments supplier’s stock valued at $103,112,000 after purchasing an additional 4,964 shares during the period. Copeland Capital Management LLC raised its stake in shares of LeMaitre Vascular by 2.3% in the 4th quarter. Copeland Capital Management LLC now owns 1,259,961 shares of the medical instruments supplier’s stock valued at $71,515,000 after purchasing an additional 28,720 shares during the period. Ranger Investment Management L.P. raised its stake in shares of LeMaitre Vascular by 1.5% in the 4th quarter. Ranger Investment Management L.P. now owns 912,503 shares of the medical instruments supplier’s stock valued at $51,794,000 after purchasing an additional 13,681 shares during the period. Finally, Congress Asset Management Co. MA increased its position in shares of LeMaitre Vascular by 12.0% in the first quarter. Congress Asset Management Co. MA now owns 666,083 shares of the medical instruments supplier’s stock valued at $44,201,000 after acquiring an additional 71,411 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

About LeMaitre Vascular

(Get Free Report)

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

Featured Stories

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.